Clinical trial
BMS-582664 in Combination With Erbitux in Patients With Advanced…
NCT00207051 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00207051 |
|---|---|
| Title | BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies |
| Official title | Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Brivanib + Cetuximab |
| Enrollment | 62 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 25, 2011 |
| Countries | Canada, Netherlands, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: